TickerFacts.

Context Therapeutics Inc. (CNTX): Capital Expenditures

Annual figures by period end, from SEC filings.

$33.9K
Year ended 2025-12-31
$55.7K
Trailing 12 months to 2026-06-30
-2.7%
3-year compound annual growth
$36.8K2021-12-31: $02022-12-31: $36.8K2023-12-31: $02024-12-31: $7.3K2025-12-31: $33.9K$33.9K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$33.9K+364.0%2026-03-23, From 2025-01-01
2024-12-31$7.3Kn/a2026-03-23, From 2024-01-01
2023-12-31$0-100.0%2025-03-20, From 2023-01-01
2022-12-31$36.8Kn/a2024-03-21, From 2022-01-01
2021-12-31$0n/a2023-03-22, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Context Therapeutics Inc. (CNTX)2025-12-31$33.9K+364.0%
Werewolf Therapeutics, Inc. (HOWL)2025-12-31$0-100.0%
Corvus Pharmaceuticals, Inc. (CRVS)2025-12-31$174.0Kn/a
Inovio Pharmaceuticals, Inc. (INO)2025-12-31$285.7K-41.4%
Rallybio Corp (RLYB)2024-12-31$0-100.0%
OnKure Therapeutics, Inc. (OKUR)2025-12-31$46.0K-11.5%
Lifevantage Corp (LFVN)2026-06-30$3.57M+160.5%
Q32 Bio Inc. (QTTB)2025-12-31$0-100.0%
DiaMedica Therapeutics Inc. (DMAC)2025-12-31$40.0K+60.0%

Compare CNTX, HOWL, CRVS, INO side by side · Screen every company in Pharmaceutical Preparations ↗